Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: A Randomized Placebo-Controlled, Double-Blind Study

Clinical Gastroenterology & Hepatology, 2023

In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 45% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.

Key Results:

  • Complete remission (CDAI score <150) was achieved by 5 of the 11 patients in the cannabis group

  • Clinical response (decrease in CDAI score of >100) was observed in 10 of the 11 patients

  • 3 of the 11 patients were weaned from steroid dependency

  • The cannabis group reported significantly less pain, and improved appetite and quality of life

Strains:

Erez

Study Population:

21 patients with Crohn’s Disease Activity Index (CDAI) scores greater than 200, who did not respond to therapy with steroids, immune-modulators, or anti-tumor agents; 11 of the patients were in the cannabis treatment study group, 10 were in the placebo control group

View PDF